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Abstract
Background: Redispensing unused medications that have been returned to outpatient pharmacies by patients may
reduce waste and healthcare costs. However, little is known regarding the extra costs associated with this process,
nor the price level of medications for which this is economically beneficial. The objective of this study was to assess
costs associated with redispensing unused medications in the pharmacy and the price level at which redispensing
becomes cost-beneficial.
Methods: A micro-costing study was conducted in four Dutch outpatient pharmacies for medications requiring
room-temperature storage and requiring refrigeration. First, the pharmacy’s necessary additional process steps and
resources for redispensing were identified. Second, time required for each process step was simulated. Third, required
resources were quantified by calculating labour, purchasing and overhead costs. Lastly, a model with different scenarios
was constructed to calculate the price of a medication package at which redispensing becomes cost-beneficial.
Results: Three main additional process steps for redispensing were identified: (1) pack medications with product quality
indicators before dispensing, (2) assess quality of medications returned to the pharmacy (temperature storage, package
integrity, expiry date) and (3a) restock medications fulfilling quality criteria or (3b) dispose of medications not fulfilling
criteria. Total time required for all steps up to restock one medication package was on average 5.3 (SD ±0.3) and 6.8
(SD ±0.3) minutes for medications stored at room-temperature and under refrigeration, respectively, and associated costs
were €5.54 and €7.61. Similar outcomes were found if a medication package would ultimately be disposed of. The price
level primarily depended upon the proportion of dispensed packages returned unused to the pharmacy and fulfilling
the quality criteria: if 5% is returned, of which 60% fulfils quality criteria, the price level was €101 per package for
medications requiring room-temperature storage and €215 per package for those requiring refrigeration. However,
if 10% is returned, of which 60% fulfils the quality criteria, the price level decreases to €53 and €109, respectively
(arbitrary proportions).
Conclusions: Redispensing unused medications in the pharmacy is at least cost-beneficial if applied to expensive
medications.
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Introduction
Pharmaceutical care, including both prescription and over-
the-counter medications, represents a substantial propor-
tion of the global healthcare budget [1]. However, up to
one-third of patients do, for various reasons, not use all
medication dispensed to them [2, 3]. It is difficult to pre-
cisely estimate the extent and costs of unused medications
because disposal occurs at various moments in time, such
as during therapy, months hereafter or even after patient’s
death, and through multiple routes, including returning
unused medications to the pharmacy, disposing of them as
household waste or flushing them down the toilet [4]. Con-
servative estimates suggest that around $5 billion and £300
million is annually wasted in the US and UK, respectively
[2, 5]. These numbers indicate that substantial resources
are wasted in the form of unused medications, which high-
lights the need for the implementation of interventions ef-
fectively reducing unnecessary medication waste.
Some packages that are returned to the pharmacy still
are completely unopened and intact [6, 7]. These medica-
tions could theoretically be redispensed in the pharmacy if
they are still of good quality, thereby reducing medication
waste and optimising the use of healthcare resources. The
discussion on the potential of redispensing unused medi-
cations as a waste-reducing intervention is not new [6, 8–
10]. However, redispensing is currently not implemented
in pharmacies [11], mainly because of legal restrictions,
uncertainty about the quality of the returned medications,
lack of knowledge regarding patient support for such an
approach and uncertainty about the cost-benefits of the
redispensing process [12, 13].
To determine whether the implementation of the redis-
pensing of unused medications in the pharmacy is
cost-beneficial, a better understanding of the costs associ-
ated with this process is required. Such an assessment will
facilitate the identification of the types of medications that
are eligible for redispensing. This study therefore aimed to
assess the costs associated with redispensing unused medi-
cations in the pharmacy. Furthermore, an attempt was
made to define the price level at which redispensing be-
comes cost-beneficial.
Methods
Study design and setting
A micro-costing study was performed in four hospital-
based outpatient pharmacies in the Netherlands between
February and June 2016. Micro-costing studies comprise
the detailed identification and measurement of all process
steps and resources used for an intervention, in this case
redispensing, which are subsequently quantified into costs
[14]. In this study, a healthcare provider’s perspective was
used, for which only the provider’s (pharmacy) costs in
the redispensing process were considered. The economic
analysis was performed according to Dutch pharmacoeco-
nomic guidelines [15].
An important prerequisite for redispensing unused medi-
cations is a guaranteed product quality. To ensure proper
storage of medications at patients’ homes, various criteria
should be monitored, such as storage temperature, light
and humidity exposure and package integrity (unopened,
intact). In addition, the medication should have a sufficient
long shelf life (here, an expiry date at least 6 months in the
future) [10]. It was assumed that an additional outer pack-
age (i.e. transparent seal bag) combined with manufac-
turer’s original primary and secondary packaging would be
sufficient to ensure proper storage in terms of light and hu-
midity exposure. This would also facilitate the assessment
of the package integrity if the seal is unbroken, ensuring
that the package remains unopened and undamaged.
Two types of medications were distinguished based on
their storage recommendations; medications requiring stor-
age at room-temperature (15–25 °C) and medications re-
quiring refrigeration at (2–8 °C). Previous research has
shown that medications requiring room-temperature stor-
age are generally stored at an appropriate temperature,
whereas medications requiring refrigeration are often stored
outside the recommended temperature range, including
below 0 °C [16, 17]. Therefore, for medications requiring re-
frigeration detailed temperature information is needed to
assess proper storage. It was assumed that a digital
temperature measurement logger system would be needed
to measure temperature constantly for these medications,
but that a simple indicator that indicates out-of-range tem-
peratures (for example, by changing colour) would be suffi-
cient for monitoring storage temperature of medications
requiring room-temperature storage.
Process identification and time measurements
To identify all the additional process steps and resources
on top of standard pharmacy practice needed to redispense
unused medications, pharmacy staff from the participating
four pharmacies were interviewed. The researchers com-
posed a list of the expected process steps and materials re-
quired, which was sent to the pharmacists prior to the
interview, and the pharmacy staff was asked to adjust the
list, adding or excluding steps and materials, and to identify
the type of pharmacy staff (e.g. technician or pharmacist)
involved in each step.
The identified process steps were simulated in each
pharmacy by staff and a researcher recorded the time
taken for each step. The simulation was performed three
times in each pharmacy. The last simulation in each of the
four pharmacies was considered most accurate and there-
fore used in the analysis (see Table 1 for the process steps
and time). Process steps that differed between medications
stored at room-temperature or under refrigeration were
simulated separately.
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Cost estimation
Direct and indirect costs were calculated for all additional
process steps and resources. Direct costs were defined as
the pharmacy’s additional costs made during the redispen-
sing process, including labour and materials. Labour costs
were calculated for each process step by multiplying the
mean time by the costs of the type of pharmacy staff in-
volved, based on the median annual salary reported by the
Royal Dutch Pharmacists Association [18]. Salary scales
were converted to a per-minute rate based on 1558 work-
ing hours per year and a 36-h working week [19]. The sal-
ary was increased with 39% to account for social charges
[19]. Material costs were calculated using purchase prices.
For medications requiring refrigeration, the purchase
prices of the digital recording system were included, as-
suming a life span of 3 years and six uses of the logger. In-
direct costs were defined as the pharmacy’s overhead costs
made through the employment of staff, the operating ac-
tivities of the facility and the quality assurance. The over-
head costs were valued at 44% of the direct costs [19]. All
costs are reported in Euros (2016) and were adjusted using
inflation rates where needed [20]. Detailed information on
the source of cost information is presented in Table 2.
Price level
To determine the price level that indicates the price of a
single medication package that would be financially eligible
Table 1 Process steps required to redispense unused medications in the pharmacy, the mean time spent on each step and the
associated costs. All process steps could be performed by a pharmacy technician unless stated otherwise






Cost (€) Mean time
(minutes; min-max)
Cost (€)
Step 1. Prepare medication before dispensing 1.6 (1.4–1.7) 2.90 2.0 (1.8–2.3) 4.30
▪ Register patient information and medication intended for dispensing in PHISa
▪ Collect a sealbag and temperature-measuring device
▪ Activate temperature-measuring device
▪ Place medication with temperature-measuring device in sealbag
▪ Inform the patient about the redispensing process
Step 2. Assess quality of returned medication 2.9 (2.4–3.6) 2.14 3.9 (3.5–4.2) 2.73
▪ Register returned medication in PHIS
▪ Place medication in a storage location if not assessed directly
▪ Determine the quality of the medication and register temperature storage,
package integrity and expiry date
▪ Place medication in storage location
▪ Review and sign off checklist by pharmacist
Step 3a. Restock medication that fulfil all quality criteria 0.8 (0.6–1.0) 0.50 0.9 (0.8–0.9) 0.58
▪ Collect medication from storage location
▪ Remove old patient label from medication package
▪ Document the restocking in PHIS
▪ Place medication in pharmacy stockb
Step 3b. Dispose of medication that not fulfil quality criteria 0.7 (0.7–0.8) 0.48 0.8 (0.7–1.0) 0.53
▪ Collect medication from storage location
▪ Document the disposal in PHIS
▪ Place medication in disposal bin
Step 4a. Collect and restock temperature loggers returned by post – – 0.4 (0.3–0.4) 1.28
Step 4b. Collect and restock temperature loggers returned as normal care 0.4 (0.3–0.4) 0.25
▪ Take logger from envelope (paid by pharmacy)
▪ Deactivate logger
▪ Place logger in stock
Total
Medication that returns to stock (step 1,2,3a) 5.3 (SD ±0.3) 5.54 6.8 (SD ±0.3) 7.61
Medication that is disposed of (step 1,2,3b) 5.2 (SD ±0.4) 5.52 6.7 (SD ±0.5) 7.56
aPharmacy’s information system, bStock adjustments and communication with the financial department could not be simulated
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for redispensing, a general model was constructed for dif-
ferent scenarios. This model was based on the following
assumptions: fixed calculated labour- material- and over-
head costs (Table 1), variation in the proportion of medica-
tion packages that are returned to the pharmacy (between
1 and 10%) and variation in the proportion of returned
medication packages that fulfil all quality criteria (between
20 and 80%). For medications requiring refrigeration, the
proportion of loggers that were returned as normal care
was set as 77%, the proportion returned by post as 4 and
19% of the dispensed loggers were assumed not to be
returned and lost that should be extra purchased (based on
personal communication with Vlieland et.al.). To define a
base case, the number of medication packages for one
therapeutic class dispensed in one pharmacy in 1 year was
in this study set as 10,000 (100%). Total costs were calcu-
lated and divided by the proportion of returned medication
packages that were assumed to fulfil all quality criteria, and
as follows the price level for the price of a single medica-
tion package was estimated (see Table 3 for example). For
estimating the price level the following formula was used:
In addition, the number needed to dispense (i.e. the
number of dispensed medication packages that are
needed in order to restock one medication package) was
calculated for each scenario to indicate the number of
medication packages that needed to obtain benefits from
redispensing. Therefore, the number of dispensed medi-
cation packages was divided by the number of medica-
tion packages that returned to stock.
Data analysis
Data were entered into Microsoft Excel 2010 and de-
scriptively analysed. Averages were expressed as means
with standard deviations (SD) or their minimum and
maximum values, and proportions were reported as
percentages.
Results
Process identification and time measurements
To identify the additional process steps and resources re-
quired to redispense unused medications in the pharmacy,
Price level ¼ Total costs in one year
Proportion of returned medication packages that fulfils quality criteria  100%
Total costs in one year ¼ cost step1  100%of dispensed packagesð Þ
þ cost step2  proportion of returned packages  100%ð Þ
þ cost step3a  proportion of returned packages that fulfils quality criteria  proportion returned  100%ð Þ
þ cost step3b  proportion of returned packages that not fulfils quality criteria  proportion returned  100%ð Þ
Additional for medications requiring refrigeration :
þ cost step4a  proportion of loggers returned by post  100%−proportion returnedð Þð Þ
þ costs step4b  dispensed loggers returned as normal care  100%−proportion returnedð Þð Þ
þ cost of loggers lost cost logger−cost of dispensed logger½   proportion of loggers lost  100%−proportion returnedð Þð Þ
þcost measuring system for one year:
Table 2 Unit cost of labour and materials
Resources Unit cost (€, 2016) Source
Pharmacy technician 0.32 Royal Dutch Pharmacists Association
Pharmacist 0.55 Royal Dutch Pharmacists Association
Sealbag 0.42 Transposafe sealbag
Temperature sensor 0.86 Telatemp warmmark time temperature indicator
Temperature logger 10.00 Safe-Rx, Confrerie Clinique
Software and licence for logger 4700.00 Safe-Rx, Confrerie Clinique
Tablet 499.00 Dell-venue 11 pro 7000
Printed paper 0.02 Staples
Printed label 0.01 Zebra Z-select 2000D label
Return envelope 0.72 Dutch post
Bekker et al. BMC Health Services Research          (2019) 19:243 Page 4 of 9
six interviews were held with eight pharmacists and one
pharmacy technician (three interviews were held with two
employees simultaneously). During the sixth interview, no
new process steps were identified and the composed list
was therefore considered comprehensive. Overall, three
main process steps were identified in redispensing unused
medications in the pharmacy: (1) add materials required
for monitoring home storage during the initial dispensing
process; (2) assess the quality of the medications returned
unused to the pharmacy in terms of temperature storage,
package integrity and expiry date; and either (3a) place
medications that fulfils all quality criteria into the phar-
macy stock or (3b) dispose of medications that not fulfils
the quality criteria. As a fourth step for refrigerated medi-
cations, patients that use their full medication course
would be requested to return the temperature loggers by
post (4a) or during their regular pharmacy visit (4b) for re-
use. For a general overview of the redispensing process
see Fig. 1, and for the process steps see Table 1.
The total time required to perform all process steps up
to restocking one medication package was on average 5.3
(SD ±0.3) minutes if requiring room-temperature storage
and 6.8 (SD ±0.3) minutes if requiring refrigeration (Table
1). Similar outcomes were found if a medication package
would ultimately be disposed of, respectively 5.2 (SD ±0.4)
minutes and 6.7 (SD ±0.5) minutes. Time differences be-
tween room-temperature stored medications and those re-
quiring refrigeration were a result of time required for
temperature logger activation and assessment compared
to the temperature sensor. For both medication types,
more than half of the time was spent on the quality assess-
ment of returned medications.
Table 3 The model to calculate the break-even point, italic variables were varied among the scenarios. In this care, 10% of dispensed
medication is returned to the pharmacy of which 60% would meet the quality criteria
Medication requiring room-temperature storage Medication requiring refrigeration
Packages Cost (€) Total cost (€) Cost (€) Total cost (€)
Step 1. 10,000 2.90 28,978 4.30 43,046
Step 2. 1000 (10%) 2.14 2138 2.73 2727
Step 3a. 600 (60%) 0.50 298 0.58 345
Step 3b. 400 (40%) 0.48 193 0.53 210
Step 4. Loggers Of 9000 – –
a. Returned by post 360 (4%) 1.28 462
b. Returned as normal care 6930 (77%) 0.25 1704
c. Lost 1710 (19%) 8.33 14,244
d. Logger system 1 year 1 2496 2496
Total 31,608 65,233
Price level per single package (Total/3a units) 53 109
Fig. 1 Flowchart of the additional process steps required to redispense unused medications in the pharmacy
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Cost estimation
The costs associated with all process steps and resources,
including direct labour- and material costs and indirect
overhead costs, required to ultimately return one medi-
cation package to stock was €5.54 if requiring room-
temperature storage, while these costs were €7.61 for a
package requiring refrigeration (Table 1). Similar costs
were found if the package would ultimately be disposed of.
Price level estimation
The price level of a single returned medication package
making redispensing cost-beneficial varied strongly for the
different scenarios and decreased when more medications
that met the quality criteria would be returned unused to
the pharmacy (Fig. 2). For instance, if 5% of the dispensed
medication packages would be returned to the pharmacy,
of which 60% would fulfil the quality criteria, the price
level would be €101.00 per package for medications re-
quiring room-temperature storage and €215.00 for those
requiring refrigeration. However, if 10% would return to
the pharmacy, of which 60% would fulfil the quality cri-
teria, the price level decreases to €53.00 and €109.00, re-
spectively. Overall, the price level is lower for medications
that require room-temperature storage compared to those
that require refrigeration.
The number needed to dispense decreased if more
medications would return to the pharmacy (Fig. 3). As
an example, if 5% would be returned to the pharmacy, of
which 60% would fulfil the quality criteria, 33 medica-
tion packages needed to be dispensed to allow for
restocking of one package.
Fig. 2 The price level for cost-beneficial redispensing for medications requiring room-temperature storage and refrigeration. The threshold depends
on the proportion of dispensed medication packages that are returned to the pharmacy and its proportion that fulfils quality criteria and can
be redispensed
Bekker et al. BMC Health Services Research          (2019) 19:243 Page 6 of 9
Discussion
In this micro-costing study, all additional process steps
and resources required to redispense unused medica-
tions in the pharmacy were explicitly identified and
quantified, and the costs associated with these were
assessed. The price-level at which redispensing unused
medications becomes cost-beneficial was identified and
found to vary strongly depending on the proportion of
dispensed packages that is returned unused to the phar-
macy that fulfil the quality criteria.
Most studies that address the potential cost savings re-
lated to redispensing unused medications include solely the
cost of the medications that remain unused [7, 21–24] and
do not take into account the associated pharmacy costs.
Glanville et al. assessed the pharmacy’s operational costs
for redispensing medications donated by patients to pa-
tients who lack health insurance and financial means to ob-
tain medication. Their analysis was based on the cost of the
donated medications, minus the pharmacy costs needed for
the quality assessment, resulting in a total net cost of the
redispensed medications [25]. In contrast, this study pro-
vides detailed information on the pharmacy costs of the
redispensing process when implemented as normal care.
Most costs that enable redispensing would already be
made during the initial dispensing of medications to the
patient, which requires additional materials to protect the
original packaging and to measure home storage
temperature conditions. To cover all pharmacy costs asso-
ciated with redispensing, the price level identified from the
analysis indicates that implementation is most likely to be
cost-beneficial for expensive medications. The price level
was estimated for one therapeutic class of which it was as-
sumed that 10.000 medication packages would be dis-
pensed in a year (base case). However, this may not be
feasible to dispense for a small pharmacy. Therefore, a gen-
eral model was created that can be used for multiple sce-
narios. Varying the quantity of dispensed medication
packages would not impact the determined price levels for
medications that require room-temperature storage. How-
ever, for medications that require refrigeration, the deter-
mined price levels are likely to decrease or increase, due to
costs related to the logger system that is needed for moni-
toring temperature storage. For these reasons also, the
price level for cost-beneficial redispensing is higher for
medications requiring refrigeration compared to those re-
quiring room-temperature storage.
The price level will decrease if more unused medica-
tions that fulfil the quality criteria are returned to the
pharmacy. However, many patients do not return their
unused medications to the pharmacy and dispose of
them through, for instance, the household waste system
instead [3, 4]. National awareness campaigns could be
implemented to increase the proportion of medication
that is returned unused to the pharmacies, which is
likely to increase the quantity eligible for redispensing.
Increasing patient awareness on proper home storage
could also increase the proportion of medications
returned to the pharmacy that meet the quality criteria.
Campaign costs were not included in this study, and if
such awareness programmes were developed, this may
affect the estimated process costs if these should be cov-
ered by the pharmacy. In addition, implementation costs
and effort for large scale workflow adjustments were not
considered. Overall, the estimated price levels indicate at
which price redispensing becomes cost-beneficial and all
costs that the pharmacy makes for this process are cov-
ered. In general, large-scale implementation involving
more therapeutic classes may decrease the direct and
Fig. 3 Number of medication packages needed to dispense, which is equally for medications requiring room temperature storage or refrigeration
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indirect costs of the pharmacy investments per package
and could provide further economic benefits.
In this study, the pharmacy’s process costs associated
with redispensing unused medications were estimated. If
a redispensing system would be implemented in practice
as normal care, one should consider how the monetary
benefits are shared among all involved stakeholders. It
can be argued that patients are less willing to return
their unused medications to the pharmacy when only
pharmacists financially benefit from redispensing. On
the other hand, pharmacists are less likely to redispense
medications if the additional costs are not covered. Ac-
cording to stakeholders, the financial benefits can be
shared among patients, pharmacists and health insur-
ance companies or used for research [10].
By redispensing unused medications that are currently
disposed of, waste can potentially be avoided. In a previ-
ous study many stakeholders including pharmacists
expressed concerns about the feasibility of implementa-
tion of redispensing in current clinical practice [11]. On
the other hand, multiple stakeholders highlighted that, in
order to realise successful implementation of redispensing,
several requirements should be met, such as extensive
public engagement, quality assurance of returned medica-
tions and an evaluated cost-benefit ratio [10, 13]. Other
studies have confirmed that the majority of patients and
professionals support redispensing if their concerns about
medication safety and quality are addressed [26, 27].
Redispensing is prohibited in some countries under
current legislation, mainly due to uncertainty about the
quality of unused medications and a fear of counterfeit
medications entering the supply chain. The latter is cur-
rently being tackled by the European Union Directives
2011/62/EU and EU2016/161, which demand that manu-
facturers add tamper indicators and unique identification
codes to their outer packaging. Furthermore, if these med-
ications are dispensed in a closed seal bag by the phar-
macy and only eligible for redispensing when returned
unopened this risk is minimised. In terms of quality assur-
ance, medications should be dispensed to patients in the
manufacturer’s original outer packaging with
tamper-evident seals and thermal devices [13, 28]. Based
on these outcomes, one can assume that most require-
ments to enable the successful implementation of redis-
pensing in practice can be fulfilled.
Strengths and limitations
The main strength of this study is the use of a
micro-costing approach, which is the most comprehensive
and precise method to estimate the costs of an interven-
tion [14]. The study also has some limitations. Primarily,
this is a simulation study and the process steps that were
identified may differ if redispensing is implemented in real
practice. However, redispensing is not routinely performed
in the pharmacy and therefore these simulations enabled a
detailed estimation of the time and resources involved,
which was required to calculate the costs. Furthermore,
pharmacy staff was not experienced in simulating the
process steps, which may have resulted in increased times.
Most process steps were similar to the normal pharmacy
practice, and three consecutive simulations were per-
formed to increase their experience, of which the last was
considered most accurate. It can be assumed that the
number of simulations performed by the pharmacy tech-
nicians was sufficient to simulate real practice. It was not
possible to simulate stock adjustments and communica-
tion with the financial department, and no training of the
pharmacy staff was included in the analysis. This may have
resulted in lower estimations of the time and cost, and ul-
timately in an underestimation of the price level. However,
this would not have altered our general findings that only
expensive medication packages are eligible for redispen-
sing. In addition, a healthcare provider’s perspective was
used for the cost estimates, and no societal costs were
taken into account. In our view, redispensing requires lim-
ited effort from society, other than the patients returning
their unused medications to the pharmacy. Most patients
visit their pharmacy regularly and one can assume that
returning unused medication would not result in add-
itional visits. Finally, this study was performed in a Dutch
outpatient pharmacy setting and as such, the outcomes
may be less generalizable to other countries. We believe
that the identified process steps will be similar between
countries, however, the unit costs that were included in
the analysis may vary. The proportion of dispensed pack-
ages that remain unused and are returned to the phar-
macy may depend on national prescribing and dispensing
policies. Therefore, a general model with various scenarios
was build that can be used in different settings as an indi-
cator to determine the price level of medications eligible
for redispensing. This model is the best case scenario
model and in the real world practice there are some more
assumptions and different probabilities which can make
these estimated costs higher.
Conclusions
This study demonstrates that the redispensing of unused
medications in the pharmacy is cost-beneficial if applied
to expensive medications. This threshold can lower if
more medications are returned unused to the pharmacy
and have been properly stored at patients’ homes of which
the quality can thus be guaranteed.
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